Thus, while both plasma and CSF NfL levels hold promise as biomarkers for early detection and monitoring of AD progression, CSF NfL may offer advantages in terms of reliability for detecting neurodegenerative processes in preclinical AD [138]. Here, NEFL is linked to Alzheimer disease.